Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide
- PMID: 15563286
- DOI: 10.1111/j.0272-4332.2004.00517.x
Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide
Abstract
Ethylene oxide (EO) has been identified as a carcinogen in laboratory animals. Although the precise mechanism of action is not known, tumors in animals exposed to EO are presumed to result from its genotoxicity. The overall weight of evidence for carcinogenicity from a large body of epidemiological data in the published literature remains limited. There is some evidence for an association between EO exposure and lympho/hematopoietic cancer mortality. Of these cancers, the evidence provided by two large cohorts with the longest follow-up is most consistent for leukemia. Together with what is known about human leukemia and EO at the molecular level, there is a body of evidence that supports a plausible mode of action for EO as a potential leukemogen. Based on a consideration of the mode of action, the events leading from EO exposure to the development of leukemia (and therefore risk) are expected to be proportional to the square of the dose. In support of this hypothesis, a quadratic dose-response model provided the best overall fit to the epidemiology data in the range of observation. Cancer dose-response assessments based on human and animal data are presented using three different assumptions for extrapolating to low doses: (1) risk is linearly proportionate to dose; (2) there is no appreciable risk at low doses (margin-of-exposure or reference dose approach); and (3) risk below the point of departure continues to be proportionate to the square of the dose. The weight of evidence for EO supports the use of a nonlinear assessment. Therefore, exposures to concentrations below 37 microg/m3 are not likely to pose an appreciable risk of leukemia in human populations. However, if quantitative estimates of risk at low doses are desired and the mode of action for EO is considered, these risks are best quantified using the quadratic estimates of cancer potency, which are approximately 3.2- to 32-fold lower, using alternative points of departure, than the linear estimates of cancer potency for EO. An approach is described for linking the selection of an appropriate point of departure to the confidence in the proposed mode of action. Despite high confidence in the proposed mode of action, a small linear component for the dose-response relationship at low concentrations cannot be ruled out conclusively. Accordingly, a unit risk value of 4.5 x 10(-8) (microg/m3)(-1) was derived for EO, with a range of unit risk values of 1.4 x 10(-8) to 1.4 x 10(-7) (microg/m3)(-1) reflecting the uncertainty associated with a theoretical linear term at low concentrations.
Similar articles
-
Cancer dose--response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity.Regul Toxicol Pharmacol. 2005 Oct;43(1):85-103. doi: 10.1016/j.yrtph.2005.06.007. Regul Toxicol Pharmacol. 2005. PMID: 16099568
-
Chloroform mode of action: implications for cancer risk assessment.Regul Toxicol Pharmacol. 1997 Oct;26(2):142-55. doi: 10.1006/rtph.1997.1161. Regul Toxicol Pharmacol. 1997. PMID: 9356278 Review.
-
Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.Regul Toxicol Pharmacol. 1998 Dec;28(3):222-5. doi: 10.1006/rtph.1998.1258. Regul Toxicol Pharmacol. 1998. PMID: 10049793
-
Cancer risk assessment for 1,3-butadiene: data integration opportunities.Chem Biol Interact. 2007 Mar 20;166(1-3):150-5. doi: 10.1016/j.cbi.2006.03.009. Epub 2006 Apr 5. Chem Biol Interact. 2007. PMID: 16647696
-
Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects.Crit Rev Toxicol. 2006 Jul-Aug;36(6-7):481-608. doi: 10.1080/10408440600851377. Crit Rev Toxicol. 2006. PMID: 16973444 Review.
Cited by
-
Positive association between blood ethylene oxide levels and metabolic syndrome: NHANES 2013-2020.Front Endocrinol (Lausanne). 2024 Apr 18;15:1365658. doi: 10.3389/fendo.2024.1365658. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38699390 Free PMC article.
-
Inverse association between blood ethylene oxide levels and obesity in the general population: NHANES 2013-2016.Front Endocrinol (Lausanne). 2022 Sep 12;13:926971. doi: 10.3389/fendo.2022.926971. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36171904 Free PMC article.
-
Mode of action-based risk assessment of genotoxic carcinogens.Arch Toxicol. 2020 Jun;94(6):1787-1877. doi: 10.1007/s00204-020-02733-2. Epub 2020 Jun 15. Arch Toxicol. 2020. PMID: 32542409 Free PMC article. Review.
-
Carcinogenicity of ethylene oxide: key findings and scientific issues.Toxicol Mech Methods. 2018 Jun;28(5):386-396. doi: 10.1080/15376516.2017.1414343. Epub 2017 Dec 21. Toxicol Mech Methods. 2018. PMID: 29210319 Free PMC article. Review.
-
Reciprocal translocations in somatic and germ cells of mice chronically exposed by inhalation to ethylene oxide: implications for risk assessment.Mutagenesis. 2010 Jan;25(1):49-55. doi: 10.1093/mutage/gep042. Epub 2009 Nov 1. Mutagenesis. 2010. PMID: 19884119 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources